Table 2.
Summary of molecular cluster detection completion and timeliness in Washington State, 2015–2019.
| Variable | 2015 | 2016 | 2017 | 2018 | Total |
|---|---|---|---|---|---|
| Number of Analyzed Clusters a | 95 | 95 | 103 | 107 | 107 |
| Number of New Cases WA State | 459 | 436 | 441 | 511 | 1847 |
| New Cases with Analyzable Genotype b | 276 (60%) | 238 (55%) | 252 (57%) | 292 (57%) | 1058 (57%) |
| Number of New Cases in All Clusters | 156 (34%) | 112 (26%) | 134 (30%) | 148 (29%) | 550 (29%) |
| Number of New Cases in Analyzed Clusters | 85 (19%) | 84 (19%) | 112 (25%) | 120 (23%) | 401 (22%) |
| Cumulative Prevalent Cases in WA State c | 12,631 | 13,051 | 13,424 | 13,764 | 15,150 |
| Prevalent Cases with Analyzable Genotype b | 6320 (50%) | 6458 (49%) | 6583 (49%) | 6733 (49%) | 7373 (49%) |
| Number of Prevalent Cases in All Clusters | 2238 (18%) | 2310 (18%) | 2389 (18%) | 2476 (18%) | 2680 (18%) |
| Number of Prevalent Cases in Analyzed Clusters | 824 (7%) | 897 (7%) | 983 (7%) | 1078 (8%) | 1157 (8%) |
| Median Days from Dx to Specimen Collection | 17 (6–30) | 14 (7–31) | 15 (7–31) | 11 (4–33) | 14 (6–31) |
| Median Days from Dx to TRACE Analysis | 821 (734–921) | 468 (353–576) | 201 (143–255) | 109 (77–137) | 291 (138–714) |
a Analyzed clusters included members of molecularly linked clusters (genetic distance 0.015) with three or more prevalent cases at one point in time between 2016 and 2018. b Analyzable genotypes include reverse transcriptase and protease sequences. c Cumulative prevalent cases include all people with diagnosed HIV who lived in Washington State at some point during the time period.